Cagrilintide: Scientific Profile

Publicado el 12 de julio de 2026

Cagrilintide (AM833; CAS 1415456-99-3) is a long-acting synthetic amylin analog designed for metabolic research use. It acts as a dual agonist of the amylin and calcitonin receptors (DACRA), modulating satiety signaling. It is studied in models of body-weight and appetite regulation, frequently in combination with GLP-1 receptor agonists.

Cagrilintide, identified by the development codes AM833 and NNC0174-0833, is a long-acting synthetic analog of human amylin, a 37-amino-acid peptide hormone co-secreted with insulin by pancreatic beta cells. With the molecular formula C194H312N54O59S2, an approximate molecular weight of 4409 g/mol, and CAS number 1415456-99-3, this compound belongs to the metabolic category and has become one of the molecules of greatest interest in preclinical and clinical research on the regulation of appetite and body weight. In the research context, Cagrilintide is used as a tool to study the satiety signaling pathways mediated by amylin and by calcitonin.

From a structural standpoint, Cagrilintide is derived from the human amylin sequence subjected to multiple peptide engineering modifications aimed at overcoming the limitations of the native hormone. Human amylin is prone to aggregation and to the formation of amyloid fibrils, and it also has a short half-life that makes it impractical as a stable experimental tool. To address this, the molecule incorporates residue substitutions that reduce the tendency to aggregate —borrowing the stabilization approach observed in pramlintide and in variants derived from rat amylin— and a lipid acylation chain that promotes reversible binding to serum albumin. This lipidation strategy, analogous to that used in other long-acting metabolic peptidomimetics, substantially prolongs the circulating half-life and allows spaced dosing regimens in research protocols, typically weekly frequency in the models studied.

The mechanism of action of Cagrilintide is described as that of a dual agonist of the amylin and calcitonin receptors, a profile abbreviated in the literature as DACRA (dual amylin and calcitonin receptor agonist). The amylin receptors are formed from the calcitonin receptor coupled to receptor activity-modifying proteins (RAMP), which generates receptor subtypes with differentiated affinities. By potently and sustainedly activating this family of receptors, mainly in nuclei of the area postrema and of the brainstem involved in the homeostatic control of intake, Cagrilintide modulates satiety signals, slows gastric emptying, and participates in the central regulation of appetite. In research models, this activation translates into a reduction of food intake and into changes in energy balance. An aspect of special experimental interest is its mechanistic complementarity with the GLP-1 receptor agonists: while the GLP-1 axis and the amylin/calcitonin axis converge on partially distinct satiety circuits, their combined action has been explored as a strategy to additively or synergistically potentiate the effects on body weight regulation.

The documented research applications of Cagrilintide focus predominantly on metabolic biology. It has been used as a reference agonist to characterize the pharmacology of amylin and calcitonin receptors, to study the neurobiology of satiety, and to model mechanisms of body weight regulation. A particularly notable line of research is its study in co-administration with semaglutide, a GLP-1 analog; this combination, known in development as CagriSema, has been the subject of clinical research aimed at evaluating the combined effects of dual activation of the amylin and incretin pathways on metabolic parameters. Cagrilintide also serves as an experimental probe to compare the profile of dual agonists against selective amylin agonists in in vitro and in vivo systems.

With regard to the level of evidence, Cagrilintide is distinguished from many obscure research peptides by having a relatively robust body of data spanning from preclinical studies to early- and late-phase clinical trials, including work on the combination with semaglutide. Its development has been conducted within a structured pharmaceutical program, which has generated more complete pharmacokinetic, pharmacodynamic, and safety data than are available for less-characterized peptides. Nevertheless, it is important to emphasize, in a framework of scientific honesty, that Cagrilintide remains a research compound: it should not be interpreted as a product with fully established efficacy or safety for any application outside the experimental context, and all of the information presented here corresponds to laboratory findings and research studies. Definitive conclusions depend on the ongoing evaluation by the scientific community.

For the researcher, Cagrilintide represents a valuable tool within the arsenal of metabolic peptide analogs, especially useful for studying the interaction between the amylin, calcitonin and incretin pathways. Its long-acting profile facilitates experimental design in spaced-administration models, and its dual mechanism allows the specific contributions of each receptor axis to be dissected. As with any research material, its handling must be carried out under appropriate laboratory protocols, with attention to the reconstitution, storage and stability conditions that preserve the structural integrity of the lipidated peptide and minimize aggregation.